Association of SARS-CoV-2 Infection With Serious Maternal Morbidity and Mortality From Obstetric Complications.
Journal
JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160
Informations de publication
Date de publication:
22 02 2022
22 02 2022
Historique:
pubmed:
8
2
2022
medline:
3
3
2022
entrez:
7
2
2022
Statut:
ppublish
Résumé
It remains unknown whether SARS-CoV-2 infection specifically increases the risk of serious obstetric morbidity. To evaluate the association of SARS-CoV-2 infection with serious maternal morbidity or mortality from common obstetric complications. Retrospective cohort study of 14 104 pregnant and postpartum patients delivered between March 1, 2020, and December 31, 2020 (with final follow-up to February 11, 2021), at 17 US hospitals participating in the Eunice Kennedy Shriver National Institute of Child Health and Human Development's Gestational Research Assessments of COVID-19 (GRAVID) Study. All patients with SARS-CoV-2 were included and compared with those without a positive SARS-CoV-2 test result who delivered on randomly selected dates over the same period. SARS-CoV-2 infection was based on a positive nucleic acid or antigen test result. Secondary analyses further stratified those with SARS-CoV-2 infection by disease severity. The primary outcome was a composite of maternal death or serious morbidity related to hypertensive disorders of pregnancy, postpartum hemorrhage, or infection other than SARS-CoV-2. The main secondary outcome was cesarean birth. Of the 14 104 included patients (mean age, 29.7 years), 2352 patients had SARS-CoV-2 infection and 11 752 did not have a positive SARS-CoV-2 test result. Compared with those without a positive SARS-CoV-2 test result, SARS-CoV-2 infection was significantly associated with the primary outcome (13.4% vs 9.2%; difference, 4.2% [95% CI, 2.8%-5.6%]; adjusted relative risk [aRR], 1.41 [95% CI, 1.23-1.61]). All 5 maternal deaths were in the SARS-CoV-2 group. SARS-CoV-2 infection was not significantly associated with cesarean birth (34.7% vs 32.4%; aRR, 1.05 [95% CI, 0.99-1.11]). Compared with those without a positive SARS-CoV-2 test result, moderate or higher COVID-19 severity (n = 586) was significantly associated with the primary outcome (26.1% vs 9.2%; difference, 16.9% [95% CI, 13.3%-20.4%]; aRR, 2.06 [95% CI, 1.73-2.46]) and the major secondary outcome of cesarean birth (45.4% vs 32.4%; difference, 12.8% [95% CI, 8.7%-16.8%]; aRR, 1.17 [95% CI, 1.07-1.28]), but mild or asymptomatic infection (n = 1766) was not significantly associated with the primary outcome (9.2% vs 9.2%; difference, 0% [95% CI, -1.4% to 1.4%]; aRR, 1.11 [95% CI, 0.94-1.32]) or cesarean birth (31.2% vs 32.4%; difference, -1.4% [95% CI, -3.6% to 0.8%]; aRR, 1.00 [95% CI, 0.93-1.07]). Among pregnant and postpartum individuals at 17 US hospitals, SARS-CoV-2 infection was associated with an increased risk for a composite outcome of maternal mortality or serious morbidity from obstetric complications.
Identifiants
pubmed: 35129581
pii: 2788985
doi: 10.1001/jama.2022.1190
pmc: PMC8822445
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
748-759Subventions
Organisme : NICHD NIH HHS
ID : UG1 HD040485
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040560
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD027869
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040500
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD053097
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD087192
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040545
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040512
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD027915
Pays : United States
Organisme : NICHD NIH HHS
ID : U10 HD036801
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD040544
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD034208
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001873
Pays : United States
Organisme : NICHD NIH HHS
ID : UG1 HD087230
Pays : United States
Investigateurs
Melissa Bickus
(M)
Francesca Facco
(F)
Janatha S Grant
(JS)
Amy M Leath
(AM)
Anna Bartholomew
(A)
Mark Landon
(M)
Kara Rood
(K)
Patrick Schneider
(P)
Heather Frey
(H)
Amanda L Nelson
(AL)
Sean Esplin
(S)
Michael W Varner
(MW)
Donna Allard
(D)
Janet Rousseau
(J)
Janet Milano
(J)
Lisa Early
(L)
Sabine Bousleiman
(S)
Ronald Wapner
(R)
Desmond Sutton
(D)
Haley Manchon
(H)
Ashley Salazar
(A)
Luis Pacheco
(L)
Shannon Clark
(S)
Hassan Harirah
(H)
Sangeeta Jain
(S)
Gayle Olson
(G)
Antonio Saad
(A)
Lindsey Allen
(L)
Guillermina Carrington
(G)
Jennifer Cornwell
(J)
Jennifer DeVolder
(J)
Wendy Dalton
(W)
Amanda Tyhulski
(A)
Ashley Mayle
(A)
Suneet P Chauhan
(SP)
Felecia Ortiz
(F)
John M Thorp
(JM)
Sally Timlin
(S)
Lena Fried
(L)
Hannah Byers
(H)
Jennifer Ferrara
(J)
Aimee Williams
(A)
Gail Mallett
(G)
Mercedes Ramos-Brinson
(M)
Samuel Parry
(S)
Meaghan McCabe
(M)
Christina Fazio
(C)
Anna Filipczak
(A)
Jennifer Craig
(J)
Lucia Muzzarelli
(L)
Abigail Roche
(A)
Elizabeth A Thom Deceased
(EA)
Crystal Nwachuku
(C)
V Lynn Flowers-Fanomezantsoa
(VL)
Monica Longo
(M)
Menachem Miodovnik
(M)
Stephanie W Archer
(SW)